NOTICE

Onegene Biotechnology was the proud host of the Chronic Inflammation Symposium 2023, held on May 11, 2023. The event highlighted the crucial role of chronic inflammation in enhancing the risk of complex diseases such as NASH, chronic kidney disease, cancer, and fibrosis.
 
Dr. Ariel Feldstein, a distinguished pioneer in the field of inflammasome and liver fibrosis research, who is currently serving as the CVP at Novo Nordisk, and Professor Sang-Kun Kim from Dongguk University, a highly-regarded scholar in NASH research in Korea, contributed their insights on the connection between NLRP3 Inflammasome activation and liver fibrosis, and shed light on its potential as a therapeutic target.
 
Dr. SJ Park, CEO of Onegene Biotechnology, unveiled OGB21502, a tetra-agonist targets NASH and liver fibrosis that combine metabolic targets such as FGF21, GLP-1R, GCGR with IL-1RA, a target associated with chronic inflammation. Additionally, Onegene unveiled UniStac, a specialized platform constructed for multi-target drug development through the process of protein-protein conjugation.